GE Healthcare’s WAVE Bioreactor™ receives Ecomagination Certification
News May 06, 2010
GE Healthcare, a unit of General Electric Company, announces the addition of the WAVE Bioreactor™, part of the ReadyToProcess portfolio, to the list of GE ecomagination approved offerings aimed at helping biotechnology and pharmaceutical companies reduce their environmental impact. In order to be recognized as an ecomagination product, WAVE had to undergo a rigorous, third party validated, review process of the operating and environmental improvements it delivers.
The WAVE Bioreactor uses disposable bags in place of permanent stainless steel reactors eliminating the need for cleaning or sterilization. In addition to reducing the amount of water and energy required during the manufacturing process, significant time is saved in the bioreactor preparation. Technologies that enable efficient, flexible and cost-effective production of biopharmaceuticals are vital to increase access and improve the quality of healthcare around the world.
“We’re committed to building a strong portfolio of ecomagination products geared to the needs of our customers around the globe,” said John Dineen, President and CEO of GE Healthcare. “Our expanding portfolio confirms our commitment to finding innovative solutions that tackle energy use and waste reduction, both of which also reduce cost in the system.”
For the equivalent output, a production facility using the WAVE Bioreactor system 500 reduces the consumption of ultra-purified water by over 66,000 liters per year, saves 42% in energy and decreases system turnaround time by more than 1300 hours per year or 92%.
Bicycle Therapeutics Expands Strategic Partnership with AstraZenecaNews
New programs added in respiratory and cardio-metabolic diseases.READ MORE
Worldwide Clinical Trials Receives 2018 CRO Leadership AwardsNews
Life Science Leader and Industry Standard Research assess 70 contract research organizations, honoring Worldwide Clinical Trials for fifth consecutive year.READ MORE
WuXi Biologics to Invest in Biologics Manufacturing Facility in SingaporeNews
WuXi Biologics' first overseas site in Asia.READ MORE
Comments | 0 ADD COMMENT
2nd Annual Artificial Intelligence in Drug Development Congress
Sep 20 - Sep 21, 2018